JANX007
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase 1Active
Key Facts
Indication
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase
Phase 1
Status
Active
Company
About Janux Therapeutics
Janux Therapeutics is on a mission to transform cancer and autoimmune disease treatment by developing precision-engineered, tumor-activated immunotherapies that maximize efficacy and safety. Founded in 2017, the company has rapidly advanced its proprietary TRACTr and TRACIr platforms, moving multiple programs into clinical development and securing high-value partnerships with Merck and Bristol Myers Squibb. Its strategy centers on solving the critical therapeutic index challenge in immuno-oncology, aiming to expand the utility of potent T-cell redirecting therapies into solid tumors, a vast and underserved market.
View full company profileTherapeutic Areas
Other Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Tomivosertib | eFFECTOR Therapeutics | Phase 2 |
| Gedatolisib + Darolutamide | Celcuity | Phase 1b/3 |
| SNP-101 (estimated) | SmartNuclide Biopharma | Phase 1 |
| AB001 (²¹²Pb-NG001) | ARTBIO | Phase 1/2 |
| AB-3028 | Arsenal Biosciences | IND-Enabling |
| PRO CAR-201A | PromiCell | Phase 1 |
| PRO CAR-202 | PromiCell | Preclinical |
| FG-3246 | Kyntra Bio | Phase 2 |
| PROVENGE (sipuleucel-T) | Dendreon | Approved |
| RP12146 | Rhizen Pharmaceuticals | Phase 1b |
| Monoclonal Antibody (undisclosed) | MetaCurUm Biotech | Preclinical |
| ModraDoc006/r | Modra Pharmaceuticals | Phase 2b |